FAIR VALUE - Narrative (Details)								3 Months Ended		12 Months Ended
	Sep. 16, 2024 USD ($)	Feb. 22, 2024 USD ($)	Dec. 27, 2023 USD ($)	Dec. 12, 2023 USD ($)	Aug. 14, 2023 USD ($) intangibleAsset	Jul. 21, 2022 USD ($) intangibleAsset	May 17, 2021 USD ($)	Dec. 31, 2024 USD ($) guarantee	Jun. 30, 2023 USD ($) intangibleAsset	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($) guarantee	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Jan. 24, 2024 shares	Nov. 19, 2021 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of money market funds								$ 84,277,000			$ 84,277,000	$ 191,841,000
Fair value interest rate derivative assets								4,897,000			$ 4,897,000	6,236,000
Achievement of milestones payment period											24 months
Contingent consideration								10,900,000			$ 10,900,000	24,000,000.0
Payments on contingent consideration											12,500,000	12,500,000	$ 0
Intangible asset impairment charge											7,600,000	0	112,000
Consideration											717,000	9,643,000	7,579,000
Intangible assets acquired												9,600,000
Intangible asset impairment charge											3,600,000	0	100,000
Gross Carrying Amount								893,825,000			893,825,000	496,708,000
Research and Development											44,581,000	34,286,000	22,318,000
Slayback Pharma Limited Liability, Company Patents and Pending Patents
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Intangible asset impairment charge											0
Akorn Holding Company, Pipeline Product
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Intangible asset impairment charge											0
Oakrum Pharma
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Remaining estimated useful lives						7 years
Intangible asset impairment charge											0
Acquired ANDA intangible assets
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Intangible asset impairment charge											7,600,000	0	$ 100,000
Gross Carrying Amount								210,497,000			210,497,000	209,780,000
Acquired ANDA intangible assets | Slayback Pharma Limited Liability, Company Patents and Pending Patents
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Consideration					$ 3,000,000.0
Intangible assets acquired					$ 2,800,000
Remaining estimated useful lives					7 years
Number of intangible assets acquired | intangibleAsset					1	4			2
Acquired ANDA intangible assets | Akorn Holding Company, Pipeline Product
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Intangible assets acquired									$ 4,300,000
Remaining estimated useful lives									7 years
Total asset purchase									$ 4,800,000
Acquired ANDA intangible assets | Oakrum Pharma
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Total asset purchase						$ 8,000,000.0
Gross Carrying Amount						7,200,000
Research and Development						1,200,000
Contingent liability not recognized, asset acquisition						$ 200,000
Acquired ANDA intangible assets | Oakrum Pharma | Measurement Input, Discount Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Intangible asset measurement input						13
Product Intellectual Property | Alvogen Inc
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Consideration			$ 2,000,000
Intangible assets acquired			$ 2,000,000
Remaining estimated useful lives			7 years
Acquired pipeline product | Slayback Pharma Limited Liability, Company Patents and Pending Patents
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Number of intangible assets acquired | intangibleAsset									1
Acquired commercial product | Slayback Pharma Limited Liability, Company Patents and Pending Patents
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Number of intangible assets acquired | intangibleAsset						1
Acquired approved product | Slayback Pharma Limited Liability, Company Patents and Pending Patents
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Number of intangible assets acquired | intangibleAsset						1
Acquired filed products | Slayback Pharma Limited Liability, Company Patents and Pending Patents
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Number of intangible assets acquired | intangibleAsset						2
CG Oncology
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Shares held (in shares) | shares														219,925
Investment, cost								28.68			28.68
Accrued Licensor Payments
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of payments								$ 6,300,000			$ 6,300,000
Up-front payment							$ 75,000,000
Number of quarterly guaranteed payment | guarantee								4			4
Additional milestone payment											$ 7,500,000
Accrued Licensor Payments | Forecast
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Collaborative arrangement royalty payable on net revenue revenue threshold										$ 70,000,000
Eye Point Agreements Member
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of payments								$ 21,000,000.0			21,000,000.0
Payments for royalties								1,900,000
Alimera Sciences, Inc | Contingent Value Rights Agreement
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration classified as equity, fair value disclosure								9,000,000.0			9,000,000.0
Alimera Sciences, Inc
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business combination, milestone payment multiplier	0.25
Contingent consideration								9,000,000			9,000,000
Research and Development											1,000,000.0
Novitium
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Additional contingent consideration								46,500,000			46,500,000
Contingent consideration								$ 10,854,000			$ 10,854,000	$ 23,984,000			$ 30,800,000
Payments on contingent consideration		$ 12,500,000		$ 12,500,000
2026 Milestone Revenue Payment | Alimera Sciences, Inc
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Revenues	$ 140,000,000.0
Business combination, divisible revenue	$ 10,000,000.0
2027 Milestone Revenue Payment | Alimera Sciences, Inc | Contingent Value Rights Agreement
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, milestone payment, CVRs agreement business days	15 days
2027 Milestone Revenue Payment | Alimera Sciences, Inc
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Revenues	$ 160,000,000.0
Business combination, divisible revenue	$ 15,000,000.0